Jekarl Dong Wook, Kim Jae Kwon, Han Jay Ho, Lee Howon, Yoo Jaeeun, Lim Jihyang, Kim Yonggoo
Departments of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, Seoul, Korea.
Departments of Laboratory Medicine, Incheon St. Mary's Hospital, College of Medicine, Incheon, Korea.
Blood Res. 2023 Apr 30;58(S1):S1-S7. doi: 10.5045/br.2023.2023004. Epub 2023 Feb 27.
Transfusion support for hematopoietic stem cell transplantation (HSCT) is an essential part of supportive care, and compatible blood should be transfused into recipients. As leukocyte antigen (HLA) matching is considered first and as the blood group does not impede HSCT, major, minor, bidirectional, and RhD incompatibilities occur that might hinder transfusion and cause adverse events. Leukocyte reduction in blood products is frequently used, and irradiation should be performed for blood products, except for plasma. To mitigate incompatibility and adverse events, local transfusion guidelines, hospital transfusion committees, and patient management should be considered.
造血干细胞移植(HSCT)的输血支持是支持性护理的重要组成部分,应向受者输注相合血液。由于首先考虑白细胞抗原(HLA)配型,且血型并不妨碍HSCT,因此会出现主要、次要、双向和RhD不相容性,这可能会阻碍输血并导致不良事件。血液制品经常进行白细胞去除,除血浆外,血液制品均应进行辐照。为减轻不相容性和不良事件,应考虑当地输血指南、医院输血委员会和患者管理。